SH
SHINIL PHARMACEUTICAL CO., LTD.
012790 | KO
Overview
Corporate Details
- ISIN(s):
- KR7012790002
- LEI:
- Country:
- South Korea
- Address:
- 충북 충주시 앙성면 본평리 산 5-1, 충주시
- Website:
- https://shinilpharma.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 841.2 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 876.9 KB | ||
| 2025-03-24 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.2 KB | ||
| 2025-03-14 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 17.2 KB | ||
| 2025-03-14 00:00 |
Annual Report
사업보고서 (2024.12)
|
Korean | 1.0 MB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.8 KB | ||
| 2025-03-07 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 87.0 KB | ||
| 2025-03-04 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당결정
|
Korean | 9.3 KB | ||
| 2024-12-16 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2024-12-16 00:00 |
Notice of Dividend Amount
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
|
Korean | 5.6 KB | ||
| 2024-11-14 00:00 |
Quarterly Report
분기보고서 (2024.09)
|
Korean | 740.8 KB | ||
| 2024-08-09 00:00 |
Interim / Quarterly Report
반기보고서 (2024.06)
|
Korean | 738.9 KB | ||
| 2024-06-05 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 20.9 KB | ||
| 2024-05-16 00:00 |
Quarterly Report
분기보고서 (2024.03)
|
Korean | 788.8 KB |
Automate Your Workflow. Get a real-time feed of all SHINIL PHARMACEUTICAL CO., LTD. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for SHINIL PHARMACEUTICAL CO., LTD.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for SHINIL PHARMACEUTICAL CO., LTD. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
South Korea
068270
South Korea
049180
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
Poland
CLN
Develops off-the-shelf cell therapies from placentas for cancer and aging-related diseases.
United States of America
CELU
United States of America
CELU
Develops medicines for sleep-wake disorders, hemophilia, and other unmet medical needs.
United States of America
CNTA
United States of America
CNTA
Developing iPSC-derived, off-the-shelf cell therapies for cancer & autoimmune diseases.
United States of America
IPSC
United States of America
IPSC
Develops epigenetic therapies for rare cardiovascular and pulmonary diseases.
Sweden
CRNO
Sweden
CRNO
Develops engineered T-cell immunotherapies for cancer using its proprietary CER platform.
United States of America
CERO
United States of America
CERO
Develops pathogen reduction technology to safeguard the global blood supply for healthcare providers.
United States of America
CERS
United States of America
CERS